Efficacy of Acalabrutinib in Very Old or Frail Patients With

Updated 04/26/2024

Status Active, not recruiting

Clinical Trial Summary

The aim of this trial is to show the efficacy, safety and feasibility of acalabrutinib in a cohort of CLL-patients ≥80 years or with a FRAIL scale score >2 (5-item questionnaire to be filled out by the patient)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Lymphoid Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid

Clinical Trial Details

NCT number	NCT04883749
Study type	Interventional
Source	German CLL Study Group
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	June 1, 2021
Completion date	December 2024

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04515238` - Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL	Phase 2
	Completed	`NCT00406809` - A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies	Phase 1/Phase 2
	Recruiting	`NCT03766763` - Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A	Phase 2
	Active, not recruiting	`NCT04608318` - Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)	Phase 3
	Recruiting	`NCT03804372` - The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide	Phase 2
	Active, not recruiting	`NCT00788684` - Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers	Phase 1
	Terminated	`NCT01518959` - The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases	Phase 3
	Completed	`NCT03787264` - Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL	Phase 2
	Recruiting	`NCT03852407` - Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning	Phase 2
	Recruiting	`NCT05350826` - Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia	N/A